This combination of two tumor-targeted bispecific antibodies (one binding CD28 to replicate costimulation and the other binding CD3 to replicate TCR engagement) should reproduce two critical components of the synapse between cancer cells and T cells and thus enhance the immune response in the TME. The gene discussed is CD28; the disease is neoplasm.